These insights may inform new therapeutic targets for treating immune impairment in sepsis, including the use of IL-7 or IFN- γ therapy or PD-1 targeting antibodies, which have been shown to reverse T cell dysfunction in murine models of sepsis and a small number of human case studies (92–94). The gene discussed is IL7; the disease is Sepsis.